Over the last decade, advances in diagnostics and treatments for lung cancer have led to the development of targeted therapies for some lung cancer subtypes. Patients with ALK+ non-small cell lung cancer (NSCLC) are appropriate candidates for such targeted therapy. This lung cancer subtype is rare (40% of NSCLCs are adenocarcinomas and only 5% of these cancers are ALK+). Biomarker testing is needed to identify patients with this subtype and to determine the most appropriate plan of care. However, this can present unique challenges for community-based providers who may only see a few ALK+ NSCLC patients each year.
Building on this project's initial findings, in 2017 ACCC conducted a series of focus groups to gain a more in-depth understanding of the landscape of testing and treating patients with ALK+ NSCLC. Then, to learn how five ACCC Cancer Program members are effectively diagnosing and managing patients with ALK+ NSCLC, in 2018 ACCC completed five site visits. Key issues related to this patient population emerging from this project include:
Read this new publication and benefit from peer-to-peer perspectives on these challenges and learn practical approaches to delivery of high quality care for patients with ALK+ NSCLC.
ACCC launched this project to support community-based practices and programs in the use of precision medicine and molecular testing in caring for patients with ALK+ NSCLC. The primary goal of this initiative is to provide examples of effective practices for utilizing appropriate molecular testing when treating patients with ALK+ NSCLC.
In 2016, this project explored current barriers and issues related to testing and treating patients with ALK+ NSCLC through an environmental scan, which was also informed by the insights of the project’s expert Advisory Committee.
Read Summary of Findings
ACCC thanks the following individuals for providing their expertise and insight to the Testing and Treating ALK+ NSCLC project:
Shirish Gadgeel, MD
Barbara Ann Karmanos Cancer Institute
Pablo Gutman, MD, MBA
Department Chair, Pathology
Holy Cross Hospital and Holy Cross Germantown Hospital
Medical Director, Holy Cross Health Cancer Institute
Mohammad Jahanzeb, MD, FACP
University of Miami
Danna Johnson, MD
Chair, Multidisciplinary Cancer Committee
Thomas Johns Cancer Hospital on the Johnston Willis Campus
Corey Langer, MD
Director, Thoracic Oncology
Professor of Medicine at the Hospital of the University of Pennsylvania
Amy Jo Pixley, MSN, RN, OCN
Oncology Nurse Navigator
Penn Medicine, Lancaster General Hospital
David R. Spigel, MD
Lung Cancer Program Director
Sarah Cannon Research Institute/Tennessee Oncology, PLLC
Alexander Spira, MD
Co-Director US Oncology Thoracic Oncology Program
Virginia Cancer Specialists, PC
H. Jack West, MD
Thoracic Oncology Program, Swedish Cancer Institute
Sponsored by Takeda Oncology